Cancer risk prediction models: A workshop on development, evaluation, and application

被引:187
作者
Freedman, AN
Seminara, D
Gail, MH
Hartge, P
Colditz, GA
Ballard-Barbash, R
Pfeiffer, RM
机构
[1] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA
[2] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 10期
关键词
D O I
10.1093/jnci/dji128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer researchers, clinicians, and the public are increasingly interested in statistical models designed to predict the occurrence of cancer. As the number and sophistication of cancer risk prediction models have grown, so too has interest in ensuring that they are appropriately applied, correctly developed, and rigorously evaluated. On May 20-21, 2004, the National Cancer Institute sponsored a workshop in which experts identified strengths and limitations of cancer and genetic susceptibility prediction models that were currently in use and under development and explored methodologic issues related to their development, evaluation, and validation. Participants also identified research priorities and resources in the areas of 1) revising existing breast cancer risk assessment models and developing new models, 2) encouraging the development of new risk models, 3) obtaining data to develop more accurate risk models, 4) supporting validation mechanisms and resources, 5) strengthening model development efforts and encouraging coordination, and 6) promoting effective cancer risk communication and decision-making.
引用
收藏
页码:715 / 723
页数:9
相关论文
共 56 条
  • [1] ANDERSON DE, 1985, CANCER, V56, P383, DOI 10.1002/1097-0142(19850715)56:2<383::AID-CNCR2820560230>3.0.CO
  • [2] 2-0
  • [3] [Anonymous], NAT INV CANC RES PLA
  • [4] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [5] A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
    Antoniou, AC
    Pharoah, PDP
    McMullan, G
    Day, NE
    Stratton, MR
    Peto, J
    Ponder, BJ
    Easton, DF
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (01) : 76 - 83
  • [6] The BOADICEA model of genetic susceptibility to breast and ovarian cancer
    Antoniou, AC
    Pharoah, PPD
    Smith, P
    Easton, DF
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1580 - 1590
  • [7] Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)
    Apicella, C
    Andrews, L
    Hodgson, SV
    Fisher, SA
    Lewis, CM
    Solomon, E
    Tucker, K
    Friedlander, M
    Bankier, A
    Southey, MC
    Venter, DJ
    Hopper, JL
    [J]. BREAST CANCER RESEARCH, 2003, 5 (06) : R206 - R216
  • [8] Variations in lung cancer risk among smokers
    Bach, PB
    Kattan, MW
    Thornquist, MD
    Kris, MG
    Tate, RC
    Barnett, MJ
    Hsieh, LJ
    Begg, CB
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (06): : 470 - 478
  • [9] BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
    Berry, DA
    Iversen, ES
    Gudbjartsson, DF
    Hiller, EH
    Garber, JE
    Peshkin, BN
    Lerman, C
    Watson, P
    Lynch, HT
    Hilsenbeck, SG
    Rubinstein, WS
    Hughes, KS
    Parmigiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2701 - 2712
  • [10] Bruner DW, 1999, ONCOLOGY-NY, V13, P325